Organ or Tissue Function
Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
Asthma, Amlitelimab, Kymab, sanofi, Immunology
Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test
Antibiotics, Probiotics, House mice, Immune response, Vaccines
Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
Roche’s Gazyva Shows Promising Results in Phase III Lupus Nephritis Trial
Gazyva, obinutuzumab, lupus nephritis, Phase III REGENCY trial, complete renal response, Roche, autoimmune disease, kidney function
X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion
X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring
Sionna Therapeutics Aims for $150 Million IPO to Advance Cystic Fibrosis Treatments
Sionna Therapeutics, IPO, cystic fibrosis, CFTR protein, NBD1 stabilizers, biotech, Nasdaq, clinical trials
Sionna Therapeutics Raises $191 Million in Upsized IPO for Cystic Fibrosis Drug Development
Sionna Therapeutics, cystic fibrosis, IPO, CFTR protein, NBD1 stabilizers, Vertex Pharmaceuticals, clinical trials
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
The Evolution of Smart Drugs: Enhancing Cognitive Performance and Beyond
Smart drugs, nootropics, cognitive enhancement, biohacking, brain performance, cognitive supplements, neuroplasticity, brain optimization.